<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CXCR4 is the receptor of stromal cell-derived factor (SDF-1) and is expressed in many types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>It also plays an important role in <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of malignant disease </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we detected the expression of CXCR4 in 81 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) by flow cytometry </plain></SENT>
<SENT sid="3" pm="."><plain>We categorized <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients into the high-expression group and low-expression group according to CXCR4 mean florescence intensity ration thresholds </plain></SENT>
<SENT sid="4" pm="."><plain>We showed that the high-expression group had a shorter overall survival time and shorter relapse-free survival time compared with those of the low-expression group (21.6 ± 1.9 vs. 46.0 ± 1.6 months, 17.0 ± 1.9 vs. 42.5 ± 2.1 months, respectively, P &lt; 0.05), and Cox regression showed that CXCR4 was an independent prognostic factor </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that the expression of CXCR4 is a useful prognostic factor for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>